Linked Life Data

1967191

Source:http://linkedlifedata.com/resource/pubmed/id/1967191

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-2-2
pubmed:abstractText
We evaluated three cellular and five serologic markers that are affected by infection with the human immunodeficiency virus type 1 (HIV-1) for their ability to predict the progression to clinical acquired immunodeficiency syndrome (AIDS). The cellular markers were the number of CD4+ T cells, the number of CD8+ T cells, and the ratio of CD4+ T cells to CD8+ T cells. The serologic markers were the serum levels of neopterin (a product of stimulated macrophages), beta 2-microglobulin, soluble interleukin-2 receptors, IgA, and HIV p24 antigen. We evaluated the usefulness of these measures as markers of the progression to AIDS prospectively, over four years, in a cohort of 395 HIV-seropositive homosexual men who were initially free of AIDS. CD4+ T cells (expressed as an absolute number, a percentage of lymphocytes, or a ratio of CD4+ to CD8+ T cells) were the best single predictor of the progression to AIDS, but the serum neopterin and beta 2-microglobulin levels each had nearly as much predictive power. The neopterin level appeared to be a slightly better predictor than the beta 2-microglobulin level. The levels of IgA, interleukin-2 receptors, and p24 antigen had less predictive value. A stepwise multivariate analysis indicated that the best predictors, in descending order, were CD4+ T cells (the percentage of lymphocytes or the CD4+: CD8+ ratio), the serum level of neopterin or beta 2-microglobulin, the level of IgA, that of interleukin-2 receptors, and that of p24 antigen. The last three markers had little additional predictive power beyond that of the first two. We conclude that of the eight markers studied, progression to AIDS was predicted most accurately by the level of CD4+ T cells in combination with the serum level of either neopterin or beta 2-microglobulin. At least one of these two serum markers, which reflect immune activation, should be used along with measurement of CD4+ T cells in disease-classification schemes and in the evaluation of responses to therapy.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0028-4793
pubmed:author
pubmed:issnType
Print
pubmed:day
18
pubmed:volume
322
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
166-72
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:1967191-Acquired Immunodeficiency Syndrome, pubmed-meshheading:1967191-Biological Markers, pubmed-meshheading:1967191-Biopterin, pubmed-meshheading:1967191-CD4-Positive T-Lymphocytes, pubmed-meshheading:1967191-Cohort Studies, pubmed-meshheading:1967191-Gene Products, gag, pubmed-meshheading:1967191-HIV Core Protein p24, pubmed-meshheading:1967191-HIV Seropositivity, pubmed-meshheading:1967191-HIV-1, pubmed-meshheading:1967191-Humans, pubmed-meshheading:1967191-Immunoglobulin A, pubmed-meshheading:1967191-Leukocyte Count, pubmed-meshheading:1967191-Male, pubmed-meshheading:1967191-Multivariate Analysis, pubmed-meshheading:1967191-Neopterin, pubmed-meshheading:1967191-Prognosis, pubmed-meshheading:1967191-Prospective Studies, pubmed-meshheading:1967191-Receptors, Interleukin-2, pubmed-meshheading:1967191-T-Lymphocytes, Regulatory, pubmed-meshheading:1967191-Viral Core Proteins, pubmed-meshheading:1967191-beta 2-Microglobulin
pubmed:year
1990
pubmed:articleTitle
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
pubmed:affiliation
Jonsson Comprehensive Cancer Center, UCLA School of Medicine 90024-1747.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't